[EN] IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS [FR] COMPOSÉS D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DE KINASE
[EN] TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE UTILISÉS COMME INHIBITEURS DE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009155389A1
公开(公告)日:2009-12-23
A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.
IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
申请人:Hynes John
公开号:US20110288085A1
公开(公告)日:2011-11-24
A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
Triazolopyridine Compounds Useful As Kinase Inhibitors
申请人:Hynes John
公开号:US20110077243A1
公开(公告)日:2011-03-31
A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.
Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
申请人:Bristol-Myers Squibb Company
公开号:US08338604B2
公开(公告)日:2012-12-25
A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
Triazolopyridine compounds useful as kinase inhibitors
申请人:Hynes John
公开号:US08410128B2
公开(公告)日:2013-04-02
A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.